Australia's vivoPharm grabs RMIT University drug discovery tech

In an all-stock deal, Australian CRO vivoPharm has acquired RMIT University's Drug Discovery Technologies (RDDT) division. The deal will result in the university grabbing a 20% stake in vivoPharm, while the CRO will uproot its headquarters from Adelaide to a suburb of Melbourne, where RDDT is located.

According to PharmaTimes, RMIT University had aimed to market RDDT globally and saw that vivoPharm, "with suitable administration, infrastructure and international marketing activities," had the capabilities to achieve that goal.  

"After six years of development, RDDT is ready to move to the next level of preclinical toxicology safety testing," said RDDT chairman Derek Young, as quoted in an article by the Australian Life Scientist.

Acquiring RDDT will also serve vivoPharm. Not only will RDDT's value boost vivoPharm, said the CRO's chairman Ian Nisbet in PharmaTimes, uprooting to the Melbourne area will provide his company with more clinical trial opportunities than Adelaide offers.

- read the article from PharmaTimes
- get more from from Australian Life Scientist

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.